Key result
Chemical or genetic correction of abnormalities in cardiac phosphorylation cascades is emerging as a potential target in the treatment of heart failure.
This review highlights the potential of targeting specific kinases and phosphatases involved in calcium cycling and excitation-contraction coupling as a therapeutic strategy for heart failure.
No takes yet. Share an insight, caveat, or question.
Targeting phosphorylation cascades remains investigational in HF; leaves open whether kinase/phosphatase correction improves clinical outcomes.
Ikeda et al. (2008) conducted a review in Heart failure. Chemical or genetic correction of abnormalities in cardiac phosphorylation cascades was evaluated. Chemical or genetic correction of abnormalities in cardiac phosphorylation cascades is emerging as a potential target in the treatment of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: